Platelet Rich Plasma for Musculoskeletal Conditions

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
University of Utah
Study ID
NCT07231471
Status
Recruiting
Apply to this trial

Conditions

  • Elbow Osteoarthritis
  • Epicondylitis of the Elbow
  • Osteoarthritis (OA)
  • Osteoarthritis (OA) of the Hip
  • Osteoarthritis (OA) of the Knee
  • Osteoarthritis (OA) of the Shoulder
  • Osteoarthritis Ankle
  • Plantar Fasciitis of Both Feet
  • Tendinopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Platelet Rich Plasma Injection — BIOLOGICAL
    Participants who are eligible and provide consent to participate will undergo a Platelet-Rich Plasma (PRP) injection. Their blood will be analyzed using a cell counter, and they will be asked to complete follow-up surveys at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months.
  • Platelet Rich Plasma Preparation — DEVICE
    The patient's blood is collected into syringes. That blood is spun in a centrifuge at high speeds, which separates their blood into layers (red blood cells, white blood cells, and plasma). The plasma portion, which contains the platelets, is transferred to a different syringe for later injection. In some cases, the plasma is spun in the centrifuge again (a "double spin" technique) to further concentrate the platelets in the plasma. The patient's blood is not exposed to air, and it is transferred by tubing between syringes with a Luer Lock connection.

Study Details

The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction. This will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.

Key Dates

Start date
Dec 29, 2025
Status verified
Mar 2026
Primary completion
Jan 1, 2035
Completion
Jan 1, 2035

Study Design

Enrollment
10,000 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Platelet Rich Plasma Injection
    Participants who are eligible and provide consent to participate will undergo a Platelet-Rich Plasma (PRP) injection. Their whole blood and the produced PRP will be analyzed using a cell counter, and they will be asked to complete follow-up surveys at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months..

Primary Outcome Measure

Visual analog score (pain) [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Utah Orthoaedic CenterSalt Lake CityUtah84111-1334
Luke Johnson, BS
[email protected]
8012133379
Daniel Cushman, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Salt Lake City, UT

By research site
University of Utah Orthoaedic Center· Salt Lake City, UT

Related Studies